This interdisciplinary synergy has fueled the recent growth of theranostics, culminating in successful phase 3 clinical trials of radiopharmaceutical therapies (RPTs) (1,2) that target the somatostatin receptors of neuroendocrine tumors and prostate-specific membrane antigen (PSMA) in prostate cancer (3,4). The gene discussed is FOLH1; the disease is prostate carcinoma.